CD163 and ovarian cancer: This is consistent with the known strong association of a favorable clinical outcome of ovarian cancer with the intratumoral presence of T cells (17), the clinical benefit of a PD1 checkpoint blockade in a subset of ovarian cancer patients (98), the up-regulation of IFN signaling in CD163+ TAM (99), and the observed preferential synthesis of IL-15 by gTAM (Figs. 6C, 6E, 8 and supplemental Fig. S11).